ArticleJournal of gastrointestinal oncology2022
Diagnostic and prognostic potential of the novel biomarker nuclear cap binding protein subunit 2 (
Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Escorting mRNAs - the multifunctional and divergent roles of cap-chaperones in post-transcriptional gene expression.Journal of cell science · 2026Review
- NCBP2 Regulates PGAM5-Mediated Mitophagy Via KIF23 Alternative Splicing To Promote Cervical Cancer ProgressionRun Title: NCBP2 Promotes Cervical Cancer Via Mitophagy.Applied biochemistry and biotechnology · 2026Article
- NCBP2 drives colorectal cancer growth and metastasis through LIPG-mediated lipid droplet accumulation.Communications biology · 2026Article
- Comprehensive profiling of RNA modification-related genes identifies RNA mExperimental & molecular medicine · 2025Article
- Nuclear RNA cap-chaperones eIF4E and NCBP2 govern distinct fates for 1000s of mRNAs uncovering an unexpected regulatory point in gene expression.bioRxiv : the preprint server for biology · 2025Article
- RNA m7G methylation regulators and targets significantly contribute to chronic obstructive pulmonary disease.Scientific reports · 2025Article
- Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer.Translational oncology · 2024Article
- The mCancers · 2023Article
- Function of TRPC1 in modulating hepatocellular carcinoma progression.Medical oncology (Northwood, London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colon adenocarcinoma (COAD) is an incurable malignancy and the third most common tumor worldwide. Advances in biomarkers screening have greatly contributed to explore the new diagnostic and prognostic biomarkers for the early detection and prognostic of COAD. However, the heterogeneity-specific nature of COAD in patients of different cancer stages, different races, genders and age are still the major challenge to clinical treatment. Methods: Gene expression, copy number (CN), and dependency score (DS) data were obtained from the Cancer Cell Line Encyclopedia (CCLE), and linear regression analyses were performed using R language. We conducted receiver operating characteristic (ROC) curve analysis and compared the area under the ROC curve area under the curve (AUC) values to evaluate the sensitivity and specificity of nuclear cap binding protein subunit 2 ( Results: Through the linear regression analysis of DS, CN, and gene expression, we determined that Conclusions: NCBP2 was the novel diagnostic and prognostic biomarker of in COAD. Our research had implications for the treatment of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.